Canfield’s flagship imaging solution now combines VECTRA® 3D imaging tools with renowned AI-driven VISIA skin analysis for masterful communication and effortless conversions. Parsippany, New Jersey – Canfield Scientific Inc., the leading provider of imaging systems, services, and products for the medical and skin care industries, has announced the official launch of their next generation VISIA® Facial Skin Analysis system.
News and Updates
Canfield Scientific is excited to announce that D2 Digital Dermatoscope has been chosen by clinicians, dermatologists, and other medical professionals as Innovative Medical Dermatological Diagnostic Device in the DERM Awards presented at DERM 2026. This recognition reinforces the exceptional quality and innovation delivered to patients worldwide in consultations enhanced by D2.
Remarkable advancements in medical dermatology continue to reshape how clinicians detect and monitor skin disease, ultimately improving patient outcomes. A recent FOXBusiness segment highlights how transformative imaging technologies are being rapidly adopted across dermatology practices, demonstrating their growing role in modern clinical workflows. At the forefront of this innovation is Canfield Scientific’s VECTRA® WB360 whole-body 3D imaging system, featured prominently in the segment.
Trusted by experts. Powered by Innovation. From January 29th to February 1st in Paris, France, Canfield will be showcasing the latest AI-driven products and services designed to enhance communications and personalize treatment planning - Booth #N201. Engage with our knowledgeable team members for expert demonstrations and previews of our medical aesthetics imaging innovations:
Canfield’s advanced VECTRA® 3D imaging technology was featured in TLC’s new ‘About Face’ series, which follows Los Angeles–based plastic surgeons Dr. Millicent Rovelo, Dr. Jason Roostaeien, and Dr. Andre Panossian as they treat patients requiring complex facial reconstruction. Throughout the series, VECTRA software is shown supporting consultations with advanced assessment and simulation capabilities.
Living in a country with the world’s highest rates of skin cancer, many Australians face significant challenges in accessing timely and affordable skin screening services. Australia 9News recently featured Prof. Rod Sinclair, MD, the director of Sinclair Dermatology, and one of his patients, reinforcing the importance of accessible whole-body skin screenings. To help reduce barriers and encourage proactive skin health, Sinclair Dermatology in East Melbourne is now offering free skin screening using Canfield Scientific’s trailblazing VECTRA® WB360 whole-body imaging system.
The Australian Skin Cancer Foundation (ASCF) launched the world’s first mobile 3D skin check service with total body 3D imaging by Canfield Scientific’s groundbreaking VECTRA® WB360 whole-body imaging system. ASCF raises awareness about sun safety and increases access to skin checks – with this new service at no cost. Following the grand opening at the popular Manly Beach, this mobile clinic will travel nationwide to provide state-of-the-art care. Special emphasis will be given to regions in Australia where access to dermatological care is limited or where wait times are prolonged.
Canfield Scientific is excited to announce that VISIA® Facial Skin Analysis system has been chosen by aestheticians, dermatologists, and other medical professionals as the Best Imaging Device in the 2025 Readers’ Choice Awards presented by MedEsthetics’ Magazine. This recognition reinforces the exceptional quality and innovation delivered to clients worldwide in consultations enhanced by VISIA.
Canfield Scientific proudly hosted its second Innovations in Imaging: A Canfield Symposium last week in Berlin, marking another successful event. This exclusive gathering brought together dermatology professionals from across the Berlin region — from private outpatient clinics to major university hospitals — creating a collaborative forum to deepen practical expertise and exchange valuable insights.
BirchBioMed Inc. has announced Hamilton Health Sciences’ (HHS) Center for Burn Research as the first clinical trial site for their Phase II / III randomized study. Based in Ontario, Canada, the HHS study site will be one of up to 10 sites involved in the research evaluating the naturally based compound, Kynurenic acid (FS2). The objective is to assess FS2 cream efficacy for scar formation in patients with burn injuries that need skin graft surgery. Canfield’s Clinical Imaging Services team configured a compliant and validated solution to provide 3D surface area measurement performed with the patient on-site and high-quality photo documentation to support the subjective rating scale assessments and measure scar healing.
